Logo

Health Canada Accepts Filling and Priority Review of Acadia’s TROFINETIDE for Rett Syndrome

Share this

Health Canada Accepts Filling and Priority Review of Acadia’s TROFINETIDE for Rett Syndrome

Shots:

  • Health Canada accepted New Drug Submission (NDS) for Acadia’s Trofinetide to treat Rett Syndrome; also granted priority review
  • P-III LAVENDER study (n=187) evaluated safety and efficacy of Trofinetide in Rett Syndrome girls & young women; At wk12, co-1EP’s RSBQ score, and CGI-I score, were statistically significant; 2EP: statistically significant measuring improvements in communication
  • Trofinetide is currently not permitted for sale in Canada, but has been approved in US for adults and pediatric patients aged >2yrs

Ref: Health Canada Image: Health Canada

Related News:- Innodem Neuroscience’s ETNA-MS Receives Health Canada’s Approval for the Treatment of Multiple Sclerosis (MS)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions